Materiomics BV

Drug development, toxicology testing and personalized medicine is restricted by unpredictable and unreliable test models leading to high faiulure rates in pre-clinical and clinical testing.

Materiomics’ iCell technology brings the solution: predictive and reliable in vitro test models.

iCell technology is an alternative for very expensive and limited- predictive animal testing in a pre-clinical setting. As a result pharmaceutical companies working with iCell technology get more successful drugs faster into clinical testing while spending less.

We are currently fundraising with full support of current shareholders and we want to bring iCell technology to full market readiness by Series A round investment of €2.5 million